What Diapro® MR is and what it is used for?
Gliclazide is a second generation sulfonylurea that has hypoglycemic
and potentially useful hemobiological properties. It stimulates the
influx of calcium ions into pancreatic beta cells and as a result
increases insulin secretion. Moreover, in vivo studies have demonstrated
changes in thrombin-induced platelet aggregation in NIDDM patients
treated with gliclazide. Non-insulin dependent diabetes mellitus
(type-II) when dietary modification has failed...
Glipita is the preparation of Sitagliptin. Sitagliptin is a new oral agent approved by the USFDA to treat type 2 diabetes with diet & exercise. It belongs to a new class of antihyperglycemic, Dipeptidyl Dipeptidase-4 (DPP-4) inhibitors. This unique class of orally active agent targets the underlying pathophysiologic processes of type 2 diabetic patients and provides an excellent alternative to the traditional agents...
Glipita-M is the preparation of sitagliptin and metformin. Sitagliptin phosphate, a dipeptidyl peptidase 4(DPP-4) inhibitor and metformin HCI, a member of the biguanide class. Glipita-M is indicated as an adjunct to diet and exercise to treat Type 2 diabetes where metfromin is not enough to improve glycemic control. FDA Approves Glipita-M For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin in a Single Tablet...